HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Labs' High-Performance Chromatography Results Don't Help Dakota Nutrition's Elderberry Claims

Executive Summary

NAD’s review was shorter than it might have been because Dakota Nutrition stopped using around 30 challenged disease claims, leaving a total of eight claims made on labels, its website and online retailers’ platforms about the amount of elderberry in its products.

You may also be interested in...



US Herbal Supplement Sales Pass $10Bn For First Time In 2020 As Consumers Hunt Immunity Health

Report by American Botanical Council from research by Nutrition Business Journal and SPINS shows sales of supplements with herbal and/or fungal ingredients increased a record 17.3% from 2019, the segment's first double-digit growth in at least 20 years.

Consumer Reports Has 'Concerns' About Echinacea, Turmeric Supplements

Nonprofit advocacy group says one third of echinacea and turmeric supplements it tested contained ingredients in amounts lower than labeled or elevated levels of lead or bacteria. Industry groups say CR used "arbitrary" standards based on preconceived, critical view of US supplement regulation.

Mandatory Product Listing: Needed For US VMS Market, Not Mandatory In User Fee Bill – CRN

Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel